Methadone Alkaloid (Methadone Hydrochloride)

Methadone is employed in the management of opioid‑related disorders and pain syndromes.

• Opioid dependence: suppresses withdrawal symptoms and supports maintenance therapy.
• Chronic pain: provides long‑acting analgesia for severe, persistent pain.
• Opioid use disorder: reduces cravings and stabilises opioid receptors.

• Methadone acts as a full agonist at the mu‑opioid receptor, binding with high affinity to inhibit nociceptive transmission and to mitigate the neurochemical changes that underlie opioid withdrawal. By maintaining steady receptor activation, it produces analgesia while preventing the surge of withdrawal symptoms that occur when opioid use is reduced or stopped.

Methadone may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Constipation: reduced bowel motility.
• Drowsiness: increased sedation, especially at treatment initiation.
• Dry mouth: reduced salivary flow.
• Sweating: excessive perspiration.
• Dizziness: light‑headed sensation.

Serious or Rare Side Effects

• Respiratory depression: marked reduction in breathing rate.
• QT interval prolongation: risk of cardiac arrhythmia.
• Severe hypotension: dangerous drop in blood pressure.
• Seizures: rare convulsive episodes.
• Allergic reactions: rash, itching, or anaphylaxis.
• Dependence or misuse: potential for abuse with prolonged use.

Methadone requires careful monitoring due to its potency and pharmacologic profile.

• Initiation: start at low dose and titrate slowly under medical supervision.
• Cardiac monitoring: obtain baseline ECG and monitor QT interval.
• Concomitant CNS depressants: avoid or use with caution to reduce respiratory risk.
• Pregnancy: assess risk‑benefit; methadone is Category C.
• Breastfeeding: weigh infant exposure against maternal benefit.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Methadone interacts with several drug classes that can alter its efficacy or safety.

Major Interactions (Avoid)

• CYP3A4 inhibitors (e.g., ketoconazole): may increase methadone levels and risk of toxicity.
• QT‑prolonging agents (e.g., quinidine): additive risk of cardiac arrhythmia.
• CNS depressants (e.g., benzodiazepines): synergistic respiratory depression.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin): may reduce methadone concentrations.
• Antidepressants (e.g., SSRIs): can affect methadone metabolism.
• Antiretrovirals (e.g., protease inhibitors): may alter plasma levels.